SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Glaser Daniel S | Director | 2026-09-08 | Grant/award | 10 | $955 |
| HUBBARD ROBERT GLENN | Director | 2026-09-08 | Grant/award | 618 | $59K |
| Harris Carla A | Director | 2026-09-08 | Grant/award | 42 | $4K |
| Hay Laura J | Director | 2026-09-08 | Grant/award | 39 | $4K |
| Johnson Jeh C. | Director | 2026-09-08 | Grant/award | 59 | $6K |
| Kennard William E | Director | 2026-09-08 | Grant/award | 294 | $28K |
| MCKENZIE DIANA | Director | 2026-09-08 | Grant/award | 157 | $15K |
| Mumenthaler Christian Stephane | Director | 2026-09-08 | Grant/award | 21 | $2K |
| TADROS RAMY | President, U.S. Business | 2026-09-08 | Grant/award | 115 | $11K |
| DEBEL MARLENE | EVP & Chief Risk Officer | 2026-08-31 | Tax withholding | 4030 | $384K |
| McCallion John D. | EVP & Chief Financial Officer | 2026-08-31 | Tax withholding | 6057 | $576K |
| PAPPAS BILL | EVP, Global Tech. & Ops. | 2026-08-31 | Tax withholding | 4030 | $384K |
| TADROS RAMY | President, U.S. Business | 2026-08-31 | Tax withholding | 4366 | $416K |
| Glaser Daniel S | Director | 2026-06-16 | Grant/award | 587 | $51K |
| HUBBARD ROBERT GLENN | Director | 2026-06-16 | Grant/award | 1016 | $89K |
| Harris Carla A | Director | 2026-06-16 | Grant/award | 587 | $51K |
| Hay Laura J | Director | 2026-06-16 | Grant/award | 587 | $51K |
| Johnson Jeh C. | Director | 2026-06-16 | Grant/award | 587 | $51K |
| Kennard William E | Director | 2026-06-16 | Grant/award | 587 | $51K |
| MCKENZIE DIANA | Director | 2026-06-16 | Grant/award | 587 | $51K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
New disclosures across liquidity, competition, and governance collectively signal a meaningfully expanded risk profile. Counterparty and clearinghouse failure risks introduce material derivatives and collateral exposure not previously articulated, while newly named competitive pressures—fee compression, passive-product shift, and talent competition—sharpen the business model threat. Governance risks are further compounded by added investment systems vulnerabilities, regulatory fine exposure, and key-person dependency on investment performance.
2 company-specific · 1 common-mode
Added specific competitive threats: fee compression, shift to passive products, asset manager competition, and talent competition. These represent newly articulated business risks.
We May Face Competition for Business Competitive pressures, based on a number of factors including service, product features, scale, price, commission structure, financial strength, investment…
Added investment systems risk, regulatory fines, client reimbursement obligations, and key personnel loss impact on investment performance and competitiveness.
Our Policies and Procedures May Be Insufficient to Protect Us From Operational Risks We may make errors in any of the large number of transactions we process through our complex administrative…
New disclosure of counterparty, clearing broker, and central clearinghouse failure risks affecting derivatives hedging, collateral requirements, and liquidity—material operational and financial risk.
Table of Contents Derivatives Risks If our counterparties, clearing brokers or central clearinghouses fail or refuse to honor their obligations under our derivatives agreements, our risks may not be…
MetLife announced the declaration of quarterly and semi-annual dividends on four series of preferred stock (Series A, D, E, and F), with specific per-share amounts and payment dates. This is a routine but material disclosure of dividend distributions to preferred shareholders, consistent with the dividend_distribution event type. The announcement specifies payment date of September 15, 2026, and record date of August 31, 2026.
View raw filing on EDGAR →MetLife issued a news release on August 5, 2026 announcing its second quarter 2026 financial results, including net income of $705 million ($1.09 per share), adjusted earnings of $1.6 billion ($2.43 per share), 7% revenue growth, 18% net investment income growth, and 17% adjusted ROE.
View raw filing on EDGAR →MetLife's Board approved a new $3.0 billion authorization to repurchase common stock on August 5, 2026, as part of the company's shareholder return program which returned over $1.1 billion to shareholders via share repurchases and common stock dividends in Q2 2026.
View raw filing on EDGAR →MetLife is furnishing preliminary, unaudited variable investment income estimates for Q2 2026 ($220–$270 million pre-tax) ahead of its formal earnings release scheduled for August 5, 2026. This is a financial disclosure under Item 7.01 (Regulation FD) that provides quantitative guidance on a material income component, though explicitly labeled preliminary and non-binding. The disclosure is material to investors assessing quarterly performance but does not fit the specific `earnings_release` category (which typically applies to the full audited earnings announcement); it is best classified as a financial guidance or preliminary results disclosure falling under `financial_other`.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of MetLife's June 16, 2026 annual shareholder meeting, including election of eleven directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed voting tallies for each director nominee and each proposal are the core content of the disclosure, making this a textbook shareholder vote results event.
View raw filing on EDGAR →